Evidence map›Paper›PMID 39443966›Full record

ArticleJournal of neuroinflammation2024

The deficient CLEC5A ameliorates the behavioral and pathological deficits via the microglial Aβ clearance in Alzheimer's disease mouse model.

Yu-Yi Lin, Wen-Han Chang, Shie-Liang Hsieh, Irene Han-Juo Cheng

Abstract read
In one paragraph

Article in Journal of neuroinflammation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yu-Yi LinInstitute of Brain Science, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Wen-Han ChangInstitute of Brain Science, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Shie-Liang HsiehImmunology Research Center, National Health Research Institutes, Zhunan, Taiwan. slhsieh@nhri.edu.tw.
Irene Han-Juo ChengInstitute of Brain Science, National Yang Ming Chiao Tung University, Taipei, Taiwan. ihjcheng@nycu.edu.tw.

Funding

National Health Research Institutes IM-113-PP-01National Science and Technology Council NSTC-112-2320-B-A49-015-MY3
6 · The paper itself

Abstract

backgroundAlzheimer's disease (AD) is a neurodegenerative disease that causes cognitive dysfunction in older adults. One of the AD pathological factors, β-Amyloid (Aβ), triggers inflammatory responses and phagocytosis of microglia. C-type lectin domain family 5 member A (CLEC5A) induces over-reactive inflammatory responses in several virus infections. Yet, the role of CLEC5A in AD progression remains unknown. This study aimed to elucidate the contribution of CLEC5A to Aβ-induced microglial activation and behavioral deficits.

methodsThe AD mouse model was crossed with Clec5a knockout mice for subsequent behavioral and pathological tests. The memory deficit was revealed by the Morris water maze, while the nociception abnormalities were examined by the von Frey filament and hotplate test. The Aβ deposition and microglia recruitment were identified by ELISA and immunohistochemistry. The inflammatory signals were identified by ELISA and western blotting. In the Clec5a knockdown microglial cell model and Clec5a knockout primary microglia, the microglial phagocytosis was revealed using the fluorescent-labeled Aβ.

resultsThe AD mice with Clec5a knockout improved Aβ-induced memory deficit and abnormal nociception. These mice have reduced Aβ deposition and increased microglia coverage surrounding the amyloid plaque, suggesting the involvement of CLEC5A in AD progression and Aβ clearance. Moreover, the phagocytosis was also increased in the Aβ-stressed Clec5a knockdown microglial cell lines and Clec5a knockout primary microglia.

conclusionThe Clec5a knockout ameliorates AD-like deficits by modulating microglial Aβ clearance. This study implies that targeting microglial Clec5a could offer a promising approach to mitigate AD progression.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesDisease Models, AnimalLectins, C-TypeMice, KnockoutMicrogliaAnimalsMaleMaze LearningMiceMice, Inbred C57BLMice, TransgenicPhagocytosisReceptors, Cell SurfaceAmyloid beta-PeptidesClec5a protein, mouseLectins, C-TypeReceptors, Cell SurfaceAlzheimer’s diseaseC-type lectin domain family 5 member A (CLEC5A)Microgliaβ-amyloid (Aβ)

Identifiers

PMID39443966
PMCPMC11515658

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.